The announcement was made during the Pharmaceutical and Biotechnology Middle East 2009 (PABME) exhibition, the first international exhibition and conference for this industry in the Middle East.
Established in early 2000 with an objective to produce life saving drugs, Hyderabad-based Vins is currently a market leader in ASVS.
With its dedicated R&D team comprising impressive scientific talent to develop new products in segments such as hematology, cardiology and oncology, Vins is expected to further boost DuBiotech's efforts in driving the region's biotechnology sector.
Marwan Abdul Aziz, Director of DuBiotech, said, "The entry of Vins Bioproducts marks another milestone in the development of Dubai's biotechnology industry. as a leading biopharmaceutical company, VINS Bioproducts' investment is a strong endorsement of DuBiotech as the Middle East's major life sciences hub."
Vins Bioproducts will set up a production facility for the first time in the Middle East. The new facility will focus its resources on strengthening the local production of ASVS and anti-rabies serum through the improved supply of safe products that conform to WHO-GMP standards. The company will also manufacture a variety of anti-cancer drugs.
S.N. Daga, Chairman of Vins Bioproducts, said, "Our new facility will play a key role in bringing innovative therapies to the Middle East that will comply with best manufacturing practices and international standards of quality control. DuBiotech's strong commitment to quality control and excellent infrastructure are some of the advantages that have compelled us to base our operations here. Although the biotechnology industry is relatively new, we believe it has the right potential to become another key industry sector in the UAE."
At present, DuBiotech hosts some of the world's top pharmaceutical companies including Amgen, Aspen Healthcare, Merck Serono, and Pfizer. With such top-tier brands, DuBiotech is establishing itself as a globally recognized centre for pharmaceutical and biotechnology industries.
Browse
related articles
Vins Bioproducts to open anti-sera production facility at DuBiotech
- United Arab Emirates: Monday, April 20 - 2009 at 15:57
- PRESS RELEASE
Dubai Biotechnology and Research Park (DuBiotech), the major life sciences hub in the Middle East and a member of TECOM Investments, today announced that Vins Bioproducts Ltd, producers of anti-snake venom serum (ASVS) and anti-rabies serum (ARS), will base its regional headquarters at the life sciences park.
Related stories
Also consider reading:
Digg
Facebook
LinkedIn
Twitter
Browse
related articles
Today's most read articles:
Log in to request more information from DuBiotech
Notes and media contacts
About DuBiotechAnnounced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a science and business park dedicated to the biotechnology industry, set within a 'free zone'. DuBiotech has two arms.
The first is the Foundation for Research and Innovation (FRI) that will initially focus on government-funded R&D in medicine and genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology.
Other areas include drug discovery, stem cell research, infectious diseases and forensic research. The second arm of DuBiotech aims to set up a biotechnology industry cluster with cutting-edge infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech-related manufacturing companies and organizations from other sectors in the industry.
DuBiotech is advised by an independent steering committee on scientific, business and ethical matters. In cooperation with global research leader, RTI International, DuBiotech is developing comprehensive regulations that address all aspects of biotech activity. Being in a 'free zone' means biotechnology firms in the park have 100% exemption from any form of taxation for 50 years, 100% business ownership and 100% repatriation of capital.
For further information, please contact:
Dr. Sabah Al-Lawati
JiWiN
Tel: +9714 375 5880 (direct)
Fax: +9714 388 8001
Posted by Rana MesbahMonday, April 20 - 2009 at 15:57 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
This article was updated on Sat May 23 2009.
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
It looks like you are using a Mac - check out our 
Web Feeds